Biogen (NASDAQ: BIIB) reported Q4 EPS of $4.05, $0.57 better than the analyst estimate of $3.48. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.44 billion.

GUIDANCE:

Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.87.

• Mid-single digit revenue decline vs 2022

For earnings history and earnings-related data on Biogen (BIIB) click here.